Viking Global
Venture Capital
Investment management firm founded in 1999 managing over $46 billion across public equity, private equity, and credit strategies.
Late Stage
Public
Healthcare
- Headquarters
- Stamford, United States
- Founded
- 1999
- Website
- vikingglobal.com
- AUM
- $57.0B
- Portfolio Companies
- 107
- Last Investment
- Jan 2026
- Geographic Focus
- United States, Global
Investment Thesis
Long-term, fundamental, research-intensive investment approach seeking highest risk-adjusted returns across global public and private markets.
Portfolio107
A
AssetWatchR
RayzeBio4M
4D Molecular TherapeuticsV
ValstoneTT
Talaris TherapeuticsST
STAR TherapeuticsNT
Neurona TherapeuticsG
Genomatica
C
CallstackV
VelosBioTB
Triveni BioP
PepGenA
AntheiaVB
Vector BioMedK
KeboolaAC
Acuren CorporationAP
Amunix PharmaceuticalsIL
International Literary PropertiesRC
Rockefeller Capital ManagementET
Eidos TherapeuticsZT
Zentera TherapeuticsG
GondolaBioAP
Amylyx PharmaceuticalsAB
Ayana BioC
CovetrusA
APIR
RevenovaOP
ORIC PharmaceuticalsN
NuvalentB
BiomEditMM
Mainstay Medical
MS
Machine SciencesNA
Nova Anchora